Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly, acquired 13 shares of common stock through a deferral plan.

Summary

• Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 13 shares of common stock on April 15, 2024.
• The shares were acquired at a price of $750.77 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Sulzberger's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally neutral to positive. The acquisition of shares by a director can be seen as a positive sign of confidence in the company.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is not indicative of any broader industry trends.

Comparison to Industry Standards

• Director stock acquisitions through deferral plans are a common practice among publicly traded companies.
• The price of $750.77 per share is consistent with the market price of Eli Lilly stock at the time of the transaction.
• Other pharmaceutical companies such as Pfizer and Merck also have similar director compensation plans.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows director confidence in the company.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Eli Lilly, Director, Stock Acquisition, Deferral Plan, Form 4, Gabrielle Sulzberger